These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 26686313)

  • 1. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
    Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J;
    Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
    Cuzick J; Sestak I; Forbes JF; Dowsett M; Knox J; Cawthorn S; Saunders C; Roche N; Mansel RE; von Minckwitz G; Bonanni B; Palva T; Howell A;
    Lancet; 2014 Mar; 383(9922):1041-8. PubMed ID: 24333009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Ganz PA; Cecchini RS; Julian TB; Margolese RG; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):857-65. PubMed ID: 26686960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
    Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
    J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
    Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
    Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
    ; Forbes JF; Cuzick J; Buzdar A; Howell A; Tobias JS; Baum M
    Lancet Oncol; 2008 Jan; 9(1):45-53. PubMed ID: 18083636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
    Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
    Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial.
    Cuzick J; Chu K; Keevil B; Brentnall AR; Howell A; Zdenkowski N; Bonanni B; Loibl S; Holli K; Evans DG; Cummings S; Dowsett M
    Lancet Oncol; 2024 Jan; 25(1):108-116. PubMed ID: 38070530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
    Baum M; Budzar AU; Cuzick J; Forbes J; Houghton JH; Klijn JG; Sahmoud T;
    Lancet; 2002 Jun; 359(9324):2131-9. PubMed ID: 12090977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
    Johnston SR; Kilburn LS; Ellis P; Dodwell D; Cameron D; Hayward L; Im YH; Braybrooke JP; Brunt AM; Cheung KL; Jyothirmayi R; Robinson A; Wardley AM; Wheatley D; Howell A; Coombes G; Sergenson N; Sin HJ; Folkerd E; Dowsett M; Bliss JM;
    Lancet Oncol; 2013 Sep; 14(10):989-98. PubMed ID: 23902874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
    Cuzick J; Sestak I; Baum M; Buzdar A; Howell A; Dowsett M; Forbes JF;
    Lancet Oncol; 2010 Dec; 11(12):1135-41. PubMed ID: 21087898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
    Buzdar AU;
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
    Tjan-Heijnen VCG; van Hellemond IEG; Peer PGM; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; De Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Boer M; de Roos WK; Linn SC; Imholz ALT; Seynaeve CM;
    Lancet Oncol; 2017 Nov; 18(11):1502-1511. PubMed ID: 29031778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
    Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
    Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
    Cuzick J; Sestak I; Forbes JF; Dowsett M; Cawthorn S; Mansel RE; Loibl S; Bonanni B; Evans DG; Howell A;
    Lancet; 2020 Jan; 395(10218):117-122. PubMed ID: 31839281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
    Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
    Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.